#1 Clinical Trials Search in Europe

Rct2100

A groundbreaking clinical trial is underway to assess the potential of RCT2100, a new inhaled medication for cystic fibrosis (CF). This study aims to evaluate the safety, tolerability, and effectiveness of RCT2100 in both healthy individuals and those living with CF. The trial consists of multiple parts, testing different dosing regimens to gather crucial data for future research and potential treatment options.

Table of Contents

What is RCT2100?

RCT2100 is a new investigational drug being studied for the treatment of Cystic Fibrosis (CF). Cystic Fibrosis is a genetic disorder that affects the lungs and other organs, causing thick, sticky mucus to build up and leading to various health problems[1]. This new medication is currently undergoing clinical trials to evaluate its safety and effectiveness in treating CF patients.

Clinical Trial Overview

The clinical trial for RCT2100 is a Phase 1/2 study, which means it’s one of the earliest stages of testing a new drug in humans. This particular study is described as a “first-in-human” trial, indicating that it’s the first time RCT2100 is being tested in people[1]. The main goals of this study are to:

  • Assess the safety of RCT2100
  • Evaluate how well the drug is tolerated by participants
  • Examine how the drug is distributed in the body (biodistribution)
  • Gather initial data on the drug’s effectiveness in CF patients

Study Design

The clinical trial is divided into two main parts[1]:

  1. Part 1 – Healthy Participants: This phase involves giving a single dose of RCT2100 to healthy volunteers. The dose will be gradually increased to determine the safest and most effective amount. This part of the study is “masked,” which means that neither the participants nor the researchers know who is receiving the actual drug and who is receiving a placebo (a substance with no active ingredients).
  2. Part 2 – CF Patients: In this phase, participants with Cystic Fibrosis will receive multiple doses of RCT2100. The dosage will again be increased gradually. This part of the study is “open-label,” meaning both the participants and researchers know that everyone is receiving the actual drug.

Safety and Tolerability Assessment

The primary focus of this clinical trial is to evaluate the safety and tolerability of RCT2100. Researchers will be closely monitoring participants for any side effects or adverse reactions. Specifically, they will be tracking[1]:

  • Adverse Events (AEs): These are any unfavorable or unintended signs, symptoms, or diseases that occur during the study, whether or not they are related to the treatment.
  • Serious Adverse Events (SAEs): These are adverse events that result in death, are life-threatening, require hospitalization, or cause significant disability.

For healthy participants in Part 1, these events will be monitored from the start of the study through Day 29. For CF patients in Part 2, monitoring will continue from Day 1 through a safety follow-up at Week 24[1].

Administration Method

RCT2100 is administered through oral inhalation using a nebulizer. A nebulizer is a device that turns liquid medicine into a fine mist that can be inhaled directly into the lungs. This method of delivery is particularly suitable for CF patients, as it allows the medication to reach the affected lung tissue directly[1].

Potential Benefits for Cystic Fibrosis Patients

While it’s important to note that RCT2100 is still in the early stages of research, and its effectiveness has not yet been proven, the development of new treatments for Cystic Fibrosis is crucial. If successful, RCT2100 could potentially offer several benefits[1]:

  • Improved lung function
  • Reduced mucus buildup
  • Better quality of life for CF patients
  • A new treatment option for those who may not respond well to existing therapies

However, it’s essential to remember that these potential benefits are speculative at this point, and more research is needed to determine the actual effects of RCT2100 on Cystic Fibrosis patients.

Aspect Details
Study Type Phase 1/2 clinical trial
Medication RCT2100 (inhaled via nebulizer)
Condition Cystic Fibrosis
Study Design Two-part study: Single ascending dose in healthy participants (Part 1), Multiple ascending doses in CF patients (Part 2)
Primary Outcomes Safety and tolerability assessed by adverse events and serious adverse events
Study Duration Part 1: 29 days, Part 2: Up to 24 weeks
Masking Part 1: Double-blind (participant, investigator), Part 2: Open-label

FAQ

  • What is RCT2100? RCT2100 is a new inhaled medication being studied for the treatment of cystic fibrosis. It is administered via a nebulizer, which turns the medication into a fine mist that can be inhaled directly into the lungs.
  • How is the clinical trial for RCT2100 structured? The trial is divided into two main parts. Part 1 involves healthy participants receiving a single dose of RCT2100 or placebo. Part 2 involves participants with cystic fibrosis receiving multiple doses of RCT2100 over 4 or 12 weeks.
  • What are the main goals of this clinical trial? The primary goals are to assess the safety and tolerability of RCT2100 in both healthy individuals and those with cystic fibrosis. The study also aims to evaluate how the medication is distributed in the body (biodistribution) and gather initial data on its effectiveness in CF patients.
  • How long does the trial last? The duration varies depending on the part of the study. For healthy participants in Part 1, the observation period is 29 days. For CF participants in Part 2, the study lasts up to 24 weeks, including a safety follow-up period.
  • What kind of results are the researchers looking for? The researchers are primarily monitoring for adverse events (AEs) and serious adverse events (SAEs) to evaluate the safety of RCT2100. They will also be gathering data on how well participants tolerate the medication and any potential benefits observed in CF patients.

Ongoing Clinical Trials on Rct2100

  • Evaluation of Safety, Tolerability, and Biodistribution of Inhaled RCT2100 in Cystic Fibrosis: A Phase 1/2 Multicenter Study

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands

Glossary

  • Cystic Fibrosis (CF): A genetic disorder that affects the lungs, pancreas, and other organs, causing thick, sticky mucus to build up and lead to infections and breathing problems.
  • RCT2100: An experimental inhaled medication being studied for the treatment of cystic fibrosis, administered via nebulizer.
  • Nebulizer: A medical device that turns liquid medication into a fine mist, allowing it to be inhaled directly into the lungs.
  • Biodistribution: The way a medication spreads throughout the body after it's administered.
  • Adverse Event (AE): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.
  • Placebo: A substance with no active medical ingredients, used as a control in clinical trials to compare against the effects of the actual medication being studied.
  • Open Label: A type of clinical trial where both the researchers and participants know which treatment is being given.
  • Masking: Also known as 'blinding,' it's a process in clinical trials where participants, researchers, or both are unaware of which treatment (active drug or placebo) is being given to reduce bias.

References